

科技资料

Neuropsychopharmacology 2

Neuropsychopharmacology 2

Proceedings of the XVIth C.I.N.P. Congress,
Munich, August 15–19, 1988

Edited by

W. E. Bunney, Jr., H. Hippius, G. Laakmann
and M. Schmauß

Springer-Verlag
Berlin Heidelberg New York
London Paris Tokyo
Hong Kong Barcelona

W. E. BUNNEY, Jr., M. D.
Professor of Psychiatry
College of Medicine
University of California at Irvine
Irvine, CA 92717, USA

Professor Dr. HANNS HIPPIUS
Professor Dr. GREGOR LAAKMANN
Psychiatrische Klinik und Poliklinik
der Universität München
Nußbaumstraße 7
8000 München 2, FRG

Priv. Doz. Dr. MAX SCHMAUSS
Bezirkskrankenhaus Augsburg
Dr.-Mack-Straße 1
8900 Augsburg, FRG

With 106 Figures

ISBN 3-540-50252-1 (in 2 Volumes) Springer-Verlag Berlin Heidelberg New York
ISBN 0-387-50252-1 (in 2 Volumes) Springer-Verlag New York Berlin Heidelberg

Library of Congress Cataloging-in-Publication Data. Collegium Internationale Neuro-psychopharmacologicum. Congress (16th : 1988 : Munich, Germany) Neuropsychopharmacology : proceedings of the XVIth C.I.N.P. Congress, Munich, August 15-19, 1988 / edited by W. E. Bunney ... [et al.]. p.cm. Includes index. ISBN 0-387-50252-1 (U.S. : alk. paper) 1. Neuropsychopharmacology-Congresses. I. Bunney, William E., II. Title. [DNLM: 1. Mental Disorders-drug therapy-congresses. 2. Nervous System-drug effects-congresses. 3. Psychopharmacology-congresses. 4. Psychotropic Drugs-pharmacology-congresses. QV 77C6975n] RM315.C58 1988 615'.78-dc20 DNLM/DLC for Library of Congress.

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, re-use of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. Duplication of this publication or parts thereof is only permitted under the provisions of the German Copyright Law of September 9, 1965, in its current version, and a copyright fee must always be paid. Violations fall under the prosecution act of the German Copyright Law.

© Springer-Verlag Berlin Heidelberg 1990
Printed in Germany

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature.

Typesetting: Fotosatz-Service Köhler, D-8700 Würzburg
2125/3130-543210 - Printed on acid-free paper

Contents of Companion Volume 1

1 Introduction

Perspectives on Dopamine as a Regulator of Brain Function. A. CARLSSON

A View of Psychopharmacology, Neuroscience, and the Major Psychoses.
W. E. BUNNEY, Jr. and B. G. BUNNEY

Lithium Is All Right, but ...

About Some Misconceptions and Some Recent Findings. M. SCHOU

Improvement in the Quality of Sleep:

A New Goal in Psychopharmacology. P. A. J. JANSSEN

The Future of Psychopharmacology and Positron Emission Tomography.

G. SEDVALL, L. FARDE, J. KOPP, S. PAULI, A. PERSSON, I. SAVIC,
and F.-A. WIESEL

2 Molecular Biology in Neuropsychopharmacology

Molecular Biological Approaches to Brain Region-

and Cell-Specific Molecules. H.-P. OTTIGER, J. B. WATSON,

F. H. BURTON, M. B. BRENNAN, G. H. TRAVIS, and J. G. SUTCLIFFE

The α_1 -Adrenergic Receptor as a Paradigm of Receptors Coupled

to Guanine Nucleotide Binding Proteins. S. COTECCHIA, D. A. SCHWINN,

R. J. LEFKOWITZ, and M. G. CARON

The Alpha-2 Adrenoceptor Vulnerability Hypothesis of Depression:

From the Clonidine Growth Hormone Stimulation Test

to the Genes Encoding a Human Alpha-2 Adrenoceptor

and Phenylethanolamine *N*-Methyltransferase. M. R. HOUBI, I. R. GOLDIN,

E. E. BAETGE, K.-U. LENTES, and W. H. BERRETTINI

3 Molecular Biology in Neurology and Psychiatry

Genetic Linkage Analysis in Early-Onset Familial Alzheimer's

Dementia. C. VAN BROECKHOVEN, H. BACKHOVENS, W. VAN HUL,

G. VAN CAMP, P. STINISSEN, A. WEHNERT, P. RAEYMAEKERS,

G. DE WINTER, M. BRUYLAND, J. GHEUENS, J. J. MARTIN,

and A. VANDENBERGHE

Molecular Genetic Approach in Affective Illness. J. MENDLEWICZ

Molecular Genetic Studies in Affective Disorders. M. BARON

4 Brain Transplants in Neurology and Psychiatry

Long-Term Changes in Parkinson's Disease Patients with Adrenal Medullary Autografts to the Caudate Nucleus.

I. MADRAZO, R. DRUCKER-COLIN, C. TORRES, F. OSTROSKY-SOLIS, R. E. FRANCO-BOURLAND, M. AGUILERA, L. GARCIA, F. ALVAREZ, J. CANDELAS, and L. QUINTANAR

5 Peripheral Cells as Pharmacological Models in Psychiatric Research

Lymphocyte Cholinergic Receptor Changes in Alzheimer's Disease.

A. ADEM

Increased Platelet Membrane Fluidity in Alzheimer's Disease:

An Initial Assessment of Specificity. G. S. ZUBENKO

[³H]Spiperone Binding to Lymphocytes in Psychiatric Disorders.

B. BONDY, B. PEUKER, and M. ACKENHEIL

Platelet Binding Sites for Serotonin Uptake Inhibitors:

Is [³H]Imipramine Binding Decreased in Depression?

P. PLENGE and E. T. MELLERUP

Changes in Platelet Serotonergic and Adrenergic Function in Patients with Depression, Panic Attack, and Mania. B. E. LEONARD

Platelet Monoamine Receptor Binding

and Tricyclic Antidepressant Treatment. P. J. COWEN and L. E. BRADDOCK

6 Endogenous Ligands for Psychotropic Drug Receptors

Endogenous Opioids and Motivational Processes:

Examination of the Neural Substrates Mediating Opioid-Induced

Reward and Aversion. T. S. SHIPPENBERG

7 Biological Markers of Affective Disorders:

Impact of Basic Neuroendocrine and Sleep Research

Sleep-Physiological Characteristics as Potential Biological Markers in Affective Disorders. D. J. KUPFER, E. FRANK, and C. L. EHLERS

Experimental Approaches for Testing the Cholinergic-Noradrenergic Imbalance Hypothesis of Affective Disorders. M. BERGER, P. FLECKENSTEIN, D. RIEMANN, and W. E. MÜLLER

Cortisol Response to Corticotropin Releasing Hormone
in Dexamethasone-Pretreated Patients with Depression.
U. VON BARDELEBEN and F. HOLSBOER

Differential Effects and Receptors of Corticosteroids in the Brain:
Implications for Psychopathophysiology. E. R. DE KLOET

Neuropeptides and Affective Disorder. J. S. SIMON and C. B. NEMEROFF

Molecular Mechanisms Controlling Proopiomelanocortin Gene Expression.
N. MARGOLIS and T. REISINE

8 α -Adrenoreceptors in Depression and for Antidepressant Effect

Antidepressant Drugs Given Repeatedly and α_1 -Adrenoceptors. J. MAJ

The Effect of Phenylethanolamine-*N*-Methyltransferase Inhibitor
on Locomotor Activity in Rats: The Role of Central α_2 -Adrenoceptor
and PNMT Activity. M. NAKAGAWARA

Neuroendocrine Studies of α_2 -Adrenoceptor Function
and the Mechanism of Action of Antidepressant Drugs. S. CHECKLEY

Levoprotiline: Clinical Therapeutic Efficacy and Tolerability. G. WENDT

α_2 -Adrenoceptor Interaction with Opiate Receptors. N. MATUSSEK

Influence of Psychotropic Drugs on Pituitary Hormone Secretion
with Special Reference to Norepinephrine Reuptake Inhibition.
G. LAAKMANN, A. HINZ, U. VODERHOLZER, R. LEHLE, H. NEUHAUSER,
M. ORTNER, and R. MEISSNER

9 The Thyroid Axis in Basic and Clinical Research

The TRH Test in Psychiatric Disorders. P. T. LOOSEN

The Blunted TSH Response to TRH – What Does It Tell Us?
Biological Monitoring During Psychopharmacological Treatment.
G. SCHÖNBECK, G. KOINIG, H. J. KUSS, B. N. GANGADHAR, G. LANGER,
R. HATZINGER, H. ASCHAUER, and F. RESCH

Alcoholism and the Thyroid Axis. J. C. GARBUTT and A. J. PRANGE, Jr.

Marginal Hypothyroidism in Mental Illness: Preliminary Assessments
of Prevalence and Significance. A. J. PRANGE, Jr., J. J. HAGGERTY, Jr.,
J. L. BROWNE, and J. D. RICE

Antithyroid Antibodies: Behavioral Significance. V. I. REUS
and N. FREIMER

The Simultaneous Use of Four Releasing Factors:
Theoretical and Practical Issues. A. HINZ, G. LAAKMANN, C. DAFFNER,
and U. VODERHOLZER

List of Contributors (Volumes 1 + 2)

Addresses are given at the beginning of the respective contribution

- Ackenheil, M. 148
Adem, A. 134
Aguilera, M. 118
Alvarez, F. 118
Arato, M. 529
Aschauer, H. 337
Backhovens, H. 86
Baetge, E. E. 70
Baldwin, D. 580
Banki, C. M. 529
Baron, M. 108
Beckmann, H. 704, 714
Berger, M. 208
Berrettini, W. H. 70
Bissette, G. 529, 549
Blanchard, J. C. 652
Bohl, J. 684
Bondy, B. 148
Bove, D. 745
Braddock, L. E. 172
Braunsteiner, H. 430
Brennan, M. B. 56
Brenneman, D. E. 722
Bridge, T. P. 737
Browne, J. L. 352
Bruyland, M. 86
Buchsbaum, M. S. 400
Bunney, B. G. 11
Bunney, Jr., W. E. 11, 400
Burton, F. H. 56
Butler, P. D. 508
Candelas, J. 118
Carlsson, A. 2
Caron, M. G. 63
Charlton, B. G. 540
Checkley, S. 286
Cook, L. L. 549
Cotecchia, S. 63
Cowburn, R. F. 668
Cowen, P. J. 172
Daffner, C. 371, 563
De Kloet, E. R. 234
De Winter, G. 86
Drucker-Colin, R. 118
Duncan, W. B. 624
Ehlers, C. L. 196
Elsenga, S. 639
Erfurth, A. 745
Evans, D. L. 520
Farde, L. 40
Feasey, K. 458
Felten, D. L. 442
Felten, S. Y. 442
Ferrier, I. N. 540
Fineberg, N. 580
Fleckenstein, P. 208
Fowler, C. J. 668
Franco-Bourland, R. E. 118
Frank, E. 196
Freimer, N. 362
Gangadhar, B. N. 337
Garbutt, J. C. 344
Garcia, L. 118
Geissler, D. 430
Gheuens, J. 86
Goebel, F. D. 745
Golden, R. N. 520
Goldin, L. R. 70
Goodwin, F. K. 737
Grahame-Smith, D. G. 608
Grohmann, R. 590
Guich, S. 400

- Haggerty, Jr., J. J. 352, 520
Hantraye, P. 409
Hardy, J. A. 668
Harris, A. 731
Hatzinger, R. 337
Heinsen, H. 704
Herold, M. 430
Hill, J. M. 731
Hinz, A. 311, 371, 563
Hippius, H. 745
Hoehe, M. R. 70
Höllt, V. 458
Hof, P. R. 474
Holsboer, F. 221
Ingraham, L. J. 737
Janssen, P. A. J. 35
Kilts, C. D. 508
Kley, N. 458
Koinig, G. 337
Konwalinka, G. 430
Kook, A. I. 731
Kopp, J. 40
Kornhuber, J. 714
Kupfer, D. J. 196
Kuß, H. J. 337
Laakmann, G. 311, 371, 563
Laduron, P. M. 652
Lagunas-Solar, M. 400
Langer, G. 337
Leenders, K. L. 418
Lefkowitz, R. J. 63
Lehle, R. 311
Lemmer, B. 684
Lentes, K.-U. 70
Leonard, B. E. 163, 598
Loch, C. 409
Loosen, P. T. 328
Madrado, I. 118
Magistretti, P. J. 474
Maj, J. 270
Margolis, N. 261
Martin, J. J. 86
Martin, J.-L. 474
Martinot, J. L. 409
Matussek, N. 306
Mazière, B. 409
Mazière, M. 409
McCartney, C. F. 520
Meissner, R. 311
Mellert, E. T. 156
Mendelson, W. B. 624
Mendlewicz, J. 92
Mengod, G. 693
Moneta, I. 458
Montgomery, S. A. 580
Morris, B. 458
Müller, O. A. 563
Müller, W. E. 208
Müller-Oerlinghausen, B. 585
Naber, D. 745
Nakagawara, M. 277
Nemeroff, C. B. 249, 508, 520, 529, 549
Neuhauser, H. 311, 563
Nilsson-Håkansson, L. 675
Nordberg, A. 675
Nuechterlein, K. 400
Ohm, T. G. 684
Ortner, M. 311
Ostrosky-Solis, F. 118
Ottiger, H.-P. 56
Ovadia, H. 435
Palacios, J. M. 693
Parry, B. L. 624
Partinen, M. 636
Pauli, S. 40
Pedersen, C. A. 520
Perro, C. 745
Persson, A. 40
Peuker, B. 148
Plenge, P. 156
Potkin, S. 400
Prange, Jr., A. J. 344, 352
Quintanar, L. 118
Raeymaekers, P. 86
Raft, D. 520
Reisine, T. 261
Resch, F. 337
Reus, V. I. 362
Rice, J. D. 352
Riederer, P. 714
Riemann, D. 208

Rossier, J. 465
Rüther, E. 590
Sack, D. A. 624
Saphier, D. 435
Savic, I. 40
Schick, U. 745
Schmauss, M. 745
Schmidt, L. G. 590
Schönbeck, G. 337
Schou, M. 27
Schwinn, D. A. 63
Sedvall, G. 40
Shippenberg, T. S. 184
Siggins, G. R. 488
Simon, J. S. 249, 520
Steinmetz, H. 684
Stinissen, P. 86
Stulzaft, O. 409
Stutzmann, J. M. 652
Sutcliffe, J. G. 56
Syrota, A. 409
Torres, C. 118
Travis, G. H. 56

Van Broeckhoven, C. 86
Van Camp, G. 86
Van den Hoofdakker, R. H. 639
Van Hul, W. 86
Vandenberghe, A. 86
Voderholzer, U. 311, 371, 563
Von Bardeleben, U. 221
Watson, J. B. 56
Wehnert, A. 86
Wehr, T. A. 624
Wendt, G. 294
Wester, P. 668
Wiedermann, C. J. 430
Wiedermann, F. J. 430
Wiesel, F.-A. 40
Winblad, B. 668
Winkelmann, M. 563
Wong, D. F. 386
Wu, J. 400
Young, L. T. 386
Young, R. S. K. 617
Zieglgänsberger, W. 488
Zubenko, G. S. 142

Contents

10 PET Imaging in Neurosciences and Psychiatry

Strategies for In Vivo Quantification of Human Neuroreceptors
by Positron Emission Tomography

D. F. WONG and L. T. YOUNG (With 4 Figures) 386

Positron Emission Tomography with [^{18}F]Deoxyglucose
and Topographic EEG in Schizophrenia

M. S. BUCHSBAUM, J. WU, K. NUECHTERLEIN, S. GUICH, S. POTKIN,
M. LAGUNAS-SOLAR, and W. E. BUNNEY, Jr. (With 1 Figure) 400

PET Imaging of D_2 Receptors in the Living Baboon and Human Brain
in Normal and Pathological Conditions Using [^{76}Br]Bromolisuride

B. MAZIÈRE, C. LOCH, P. HANTRAYE, O. STULZAF, J. L. MARTINOT,
A. SYROTA, and M. MAZIÈRE (With 7 Figures) 409

Dopamine Metabolism in Brain Studied with PET

K. L. LEENDERS (With 7 Figures). 418

11 The Brain-Immune System Interactions

Activation of Human Monocytes by the Neuropeptide Substance P
and by Immune Interferon- γ : Evidence of Different Mechanisms

F. J. WIEDERMANN, C. J. WIEDERMANN, M. HEROLD, D. GEISSLER,
G. KONWALINKA, and H. BRAUNSTEINER (With 1 Figure) 430

Neuroimmunomodulation: Electrophysiological Patterns in Brain
During the Course of Immune Responses

H. OVADIA and D. SAPHIER (With 6 Figures) 435

Sympathetic Noradrenergic Neural Contacts with Lymphocytes
and Macrophages in the Splenic White Pulp of the Rat:

Site of Possible Bidirectional Communication

and Local Regulation Between the Nervous and Immune Systems

S. Y. FELTEN and D. L. FELTEN (With 2 Figures) 442

12 Neuropeptides: Basic Research

Gene Expression of Opioid Peptides is Regulated by Electrical Activity V. HÖLLT, K. FEASEY, N. KLEY, I. MONETA, and B. MORRIS (With 3 Figures)	458
Biosynthesis of Opioid Peptides J. ROSSIER (With 6 Figures)	465
Modulation of Energy Metabolism by Vasoactive Intestinal Peptide, Adenosine, and K^+ in the Cerebral Cortex: Focus on the Cellular Level P. J. MAGISTRETTI, J.-L. MARTIN, and P. R. HOF (With 2 Figures) . . .	474
How Neuropeptides Alter Neuronal Excitability G. R. SIGGINS and W. ZIEGLGÄNSBERGER (With 2 Figures)	488

13 Clinical Aspects of Neuropeptide Research

Corticotropin Releasing Factor, the Amygdaloid Complex, and Depression: A Hypothetical Interrelationship C. D. KILTS, P. D. BUTLER, and C. B. NEMEROFF	508
Clinical Aspects of Neuropeptide Research D. L. EVANS, R. N. GOLDEN, C. B. NEMEROFF, C. A. PEDERSEN, C. F. MCCARTNEY, J. J. HAGGERTY, Jr., J. S. SIMON, and D. RAFT. . . .	520
Thyroid Axis Stimulation Tests in Psychiatry C. M. BANKI, M. ARATO, G. BISSETTE, and C. B. NEMEROFF (With 5 Figures)	529
Corticotropin-Releasing Hormone and the Proopiomelanocortin-Derived Peptides in Depression B. G. CHARLTON and I. N. FERRIER	540
Alterations in Neuropeptide Systems in Alzheimer's Disease L. L. COOK, G. BISSETTE, and C. B. NEMEROFF.	549
Endocrine Response to Tricyclic Antidepressants and Peptides in Depression with Special Regard to Growth Hormone Secretion G. LAAKMANN, A. HINZ, U. VODERHOLZER, H. NEUHAUSER, C. DAFFNER, M. WINKELMANN, and O. A. MÜLLER (With 4 Figures) . .	563

14 Postmarketing Surveillance of Psychotropic Drugs

Relative Toxicity of Antidepressants Using Reports Independent of Observer Bias S. A. MONTGOMERY, D. BALDWIN, and N. FINEBERG	580
---	-----

Assessment of Drug Utilization and Adverse Drug Reactions in the Federal Republic of Germany B. MÜLLER-OERLINGHAUSEN (With 3 Figures)	585
Drug Surveillance in Psychiatric Patients in the Federal Republic of Germany R. GROHMANN, L. G. SCHMIDT, and E. RÜTHER (With 3 Figures)	590
Surveillance of Toxicity of Antidepressants B. E. LEONARD	598
A General Perspective of Post-Marketing Surveillance D. G. GRAHAME-SMITH	608
Surveillance of Adverse Drug Reactions in the United States R. S. K. YOUNG	617

15 Pharmacological Aspects of Sleep and Sleep Disorders

Sleep and Sleep Deprivation Studies in Patients with Premenstrual Depression B. L. PARRY, W. B. MENDELSON, W. B. DUNCAN, D. A. SACK, and T. A. WEHR	624
Epidemiological Aspects of Insomnia Research M. PARTINEN	636
Antidepressant Medication and Total Sleep Deprivation in Depressives S. ELSENGA and R. H. VAN DEN HOOFDACKER (With 8 Figures)	639
Pharmacology of New Sleep-Improving Drugs J. M. STUTZMANN, P. M. LADURON, and J. C. BLANCHARD (With 11 Figures)	652

16 Drug Effects and Morphological Investigations in Human Postmortem Tissue

Neurotransmitter Function in Post-Mortem Human Brain: An Overview C. J. FOWLER, R. F. COWBURN, J. A. HARDY, P. WESTER, and B. WINBLAD (With 2 Figures)	668
Modulation of Cholinergic Activity in Alzheimer Brains by Potential Drugs A. NORDBERG and L. NILSSON-HÅKANSSON (With 10 Figures)	675
Reduced Stimulated Adenylate Cyclase Activity in Postmortem Hippocampus of Demented Patients T. G. OHM, J. BOHL, H. STEINMETZ, and B. LEMMER (With 2 Figures)	684

Molecular Neuropathology: The Study of Transmitter and Receptor Expression in Human Postmortem Materials by In Situ Hybridization and Receptor Autoradiography G. MENGOD and J. M. PALACIOS (With 4 Figures)	693
Further Cytoarchitectonic and Quantitative Studies in the Entorhinal Region of Schizophrenics and Normal Controls by Means of a Modified Nissl Technique H. HEINSEN and H. BECKMANN (With 3 Figures)	704
The Dopaminergic and Glutamatergic Systems in Schizophrenia J. KORNHUBER, P. RIEDERER, and H. BECKMANN (With 2 Figures)	714
17 AIDS	
Peptide Intervention in Neuronal Death Caused by the HIV External Envelope Protein: Clinical Implications D. E. BRENNEMAN (With 5 Figures)	722
AIDS as a Neuropeptide Disorder: Does HIV Bind to a VIP Receptor? J. M. HILL, A. I. KOOK, and A. HARRIS (With 3 Figures)	731
Neuropsychiatry of AIDS: Clinical Presentation and Treatment Research T. P. BRIDGE, L. J. INGRAHAM, and F. K. GOODWIN.	737
Psychiatric Symptoms and Neuropsychological Deficits in HIV Infection D. NABER, C. PERRO, U. SCHICK, M. SCHMAUSS, A. ERFURTH, D. BOVE, F. D. GOEBEL, and H. HIPPIUS	745
Appendix	757
Subject Index	803

Strategies for In Vivo Quantification of Human Neuroreceptors by Positron Emission Tomography *

D. F. WONG and L. T. YOUNG¹

Introduction

At the present time, a number of groups of investigators are studying neuroreceptors and neurotransmitter systems with positron emission tomography (PET). In vivo quantification of neuroreceptors has been accomplished only in the past decade, and techniques are therefore still undergoing modification and validation. One of the earliest findings suggested a decline in the density of central dopamine D₂ neuroreceptors with age and different slopes of density versus age for men and women (Wong et al. 1984). Although there has been a steady improvement in imaging methods, controversy has surrounded many of the findings obtained with these techniques. Nevertheless, potential findings in neuropsychiatric illnesses at least stimulate future investigation and may, more optimistically, provide real insight into pathophysiology.

Abnormalities in neuroreceptor binding (and in some cases neuroreceptor densities) have been demonstrated in a number of neuropsychiatric disorders including schizophrenia (Wong et al. 1986c; Farde et al. 1987), temporal lobe epilepsy (Frost et al. 1988), poststroke depression (Mayberg et al. 1988), bipolar affective disorder (Wong et al. 1988), and Tourette's syndrome (Wong et al. 1988). The complexity and novelty of PET neuroreceptor imaging procedures indicate that improvements are still needed, and that the reliability of results obtained with such techniques may be questioned.

Very recently, two studies of drug-naïve schizophrenics using different radioligands, PET techniques, and patient populations had markedly different results. One study completed in 1986 at the Johns Hopkins Medical Institutions in Baltimore (Wong et al. 1986c) demonstrated an approximately twofold elevation in D₂ receptor density (B_{\max}) in ten drug-naïve schizophrenics and five drug-free schizophrenics as compared to 11 normal controls (Fig. 1) using the ligand [¹¹C]N-methylspiperone (NMSP). These elevated densities continue to be demonstrated in our sample, which has since been expanded to 20 drug-

* This work was supported in part by NIMH Contract R01 MH42821 (to D.F.W.) and the Medical Council of Canada (to L.T.Y.).

¹ Department of Radiology and Nuclear Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.




Fig. 1. Dopamine D_2 receptor density (B_{max}) in the caudate nucleus in normal volunteers (N) and in drug-naive (SN) and drug-treated (ST) schizophrenics. Solid horizontal lines, mean values in each group. For the drug-naive group this line is the value for the eight subjects who had only a single 7.5-mg dose of haloperidol before their second PET scan (43.3 ± 5.7 pmol/g). Dotted line, mean of all ten subjects, including the two who received more than a single dose of haloperidol before their second PET scan (average receptor density in this group, 41.7 ± 4.6 pmol/g). Mean receptor densities for the normal volunteers and the drug-treated group were 16.6 ± 2.5 and 43.3 ± 4.7 pmol/g, respectively. There was a significant difference (t test with Bonferroni correction for multiple inference) between either the eight or ten drug-naive or the drug-treated schizophrenics and the normal subjects. (From Wong et al. 1986c)

naive schizophrenics, with a continuation in these elevations (Tune et al. 1989; Wong et al. 1989a, c). In 1987, a Swedish group at the Karolinska Institute using PET with the radioligand [^{11}C]raclopride did not demonstrate significant differences in D_2 receptor density or affinity between 15 drug-naive schizophrenics and normal controls (Farde et al. 1987). It has become clear that there are many factors which might contribute to such markedly different findings (Table 1). For present purposes, these divergent results between two studies of the same neuroreceptor in the same disorder serve as an example to illustrate some important considerations regarding PET neuroreceptor imaging in living human brain.

It is of interest that a similar problem occurred in the study of patients at risk to develop Huntington's disease using the [^{18}F]2-deoxyglucose (FDG) technique to measure cerebral glucose metabolism. Although two studies showed reductions in caudate glucose metabolism in subjects at risk for Huntington's disease (Mazziotta et al. 1987; Hayden et al. 1987), a later study did not (Young et al. 1987). These results are surprising since patients in all

Table 1. Comparison of Johns Hopkins University (JHU) and Karolinska Institute PET D₂ dopamine receptor studies

	JHU ^a	Karolinska ^b
<i>n</i>	10	15
Age		
Patients	31.2 ± 3.6	24.0 ± 3.7
Controls	24.3 ± 2.0	29.1 ± 4.6
Duration of illness	4.7 years	1.9 years ^c
Ligand	[¹¹ C]NMSP	[¹¹ C]Raclopride
<i>B</i> _{max} determination	Two PET scans with Wolfe plot and model comparison	Two PET scans with Scatchard plot

^a Wong et al. (1986a, c).^b Farde et al. (1987).^c At the time of the scan, one-half of the subjects had been ill for less than 6 months.

three studies met the same diagnostic criteria and were all studied in the same country. Significant differences are present in the methods of image analysis which may in part account for divergent findings. These results are of particular concern since measurement of cerebral glucose metabolism with FDG is probably the most well-established PET technique. Following a number of important methodological issues in the development and interpretation of PET, neuroreceptor studies are considered.

Methodological Issues

Patient and Control Population

Perhaps partly due to the complex technology associated with PET scanning, an important issue in interpreting studies which attempt to quantify neuroreceptors is often neglected: the patient and control populations. Diagnostic criteria and clinical characteristics of patients are fundamental in designing and interpreting clinical investigations, particularly in psychiatry which has few disease markers or definitive diagnostic tests. Schizophrenia is a chronic debilitating neuropsychiatric disease which usually begins in adolescence or early adulthood (Lehmann and Cancro 1985). There are widely varying clinical presentations, in addition to variable symptoms occurring at different stages of illness. There appears to be a heterogeneous population of patients as well as differences in the acute versus chronic stages of this disorder. It is plausible that neurochemical findings in schizophrenia may become more prominent at later stages of illness rather than at the onset of symptoms. This situation would be consistent with computed tomography scan abnormalities which were found to be more apparent in chronic versus acute schizophrenia (Luchins 1982).

Regarding the controversy over D_2 receptor findings in the Hopkins versus Karolinska studies (Table 1), patients in the study from Johns Hopkins were older (mean age 31 ± 4 years, $n = 10$) and had been ill for a longer time (4.7 years) compared with the Swedish patients (mean age 24 ± 4 , $n = 15$; mean duration of illness, 1.9 years). If D_2 receptor changes occur at a later stage of illness, such clinical issues may be relevant. The duration of illness, time of scanning relative to the first episode, the presence or absence of psychotic features, premorbid personality traits, and predominant positive or negative symptoms are just some examples of potentially relevant factors which may be important in interpreting PET neuroreceptor imaging in schizophrenia. Generally, it can be stated that there are relevant issues which relate to typical clinical manifestations of a particular neuropsychiatric disorder which must be carefully considered in the design and interpretation of a PET study.

In addition to clinical issues in the patient group, attention must be directed towards selecting appropriate control groups. Matching on the basis of age sex is extremely important in the case of D_2 receptor imaging, in which a fall with age (Wong et al. 1984) in addition to sex differences was suggested and continues to be found with more sophisticated models (Wong et al. 1986a, c, 1988, 1989a, c). Moreover, socioeconomic status and level of education need also be considered. In practice, it is difficult to recruit subject groups matched on these variables for such complex procedures as PET neuroreceptor studies. Since an essential feature of schizophrenia is the presence of impairment in social functioning (American Psychiatric Association 1987), matching on socioeconomic status and level of education may not be an appropriate. It is not clear, however, how important these variables are in the design or interpretation of PET studies. Indeed, there are many other variables which may potentially confound experimental design. All need to be considered and subject groups matched on important variables.

Radioligand Pharmacology

Important initial considerations in choosing a PET strategy to quantify a neuroreceptor in vivo in human brain include pharmacologic parameters of the proposed radioligand, such as the kinetics and affinity of binding, selectivity, and specificity. In general, PET radioligands can be divided into two types, those which reach a quasi-equilibrium during the PET scan and those which do not. The first type of ligand, for example raclopride, is rapidly reversible and displays considerable dissociation during the time interval of the PET scan. In the latter group, because of the time frame of the PET scan which is based on the short half-life of typical radioisotopes (^{11}C , $t_{1/2} = 20$ min; ^{18}F , $t_{1/2} = 110$ min), these nonequilibrating ligands, such as NMSP, can be considered to bind "irreversibly" because of minimal dissociation from brain regions. Perhaps this binding parameter is the most important factor in the design and development of a model to quantify neuroreceptors with the particular PET radioligand. Specific modelling issues are addressed below.